drugset / Trial / NCT00419445
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
RandomizedCrossoverDouble-blindTreatment
Summary
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GTS-21 | Small molecule | 25 mg | — |
| Comparator | GTS-21 | Small molecule | 75 mg | — |
| Comparator | GTS-21 | Small molecule | 150 mg | — |